Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;73(7):1056-1057.
doi: 10.1002/acr.24457. Epub 2021 Jun 4.

Ustekinumab in Giant Cell Arteritis: Comment on the Article by Matza et al

Richard Conway  1 , Eamonn S Molloy  2
Affiliations
Comment

Ustekinumab in Giant Cell Arteritis: Comment on the Article by Matza et al

Richard Conway et al. Arthritis Care Res (Hoboken). 2021 Jul.
No abstract available

PubMed Disclaimer

Comment in

  • Reply.
    Matza MA, Fernandes AD, Stone JH, Unizony SH. Matza MA, et al. Arthritis Care Res (Hoboken). 2021 Jul;73(7):1057-1058. doi: 10.1002/acr.24454. Epub 2021 Jun 4. Arthritis Care Res (Hoboken). 2021. PMID: 32961035 No abstract available.

Comment on

References

    1. Matza MA, Fernandes AD, Stone JH, Unizony SH. Ustekinumab for the treatment of giant cell arteritis. Arthritis Care Res (Hoboken) 2021;73:893-7.
    1. Conway R, O’Neill L, McCarthy GM, Murphy CC, Fabre A, Kennedy S, et al. Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis. Ann Rheum Dis 2018;77:1815-24.
    1. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317-28.
    1. Mainbourg S, Addario A, Samson M, Puéchal X, François M, Durupt S, et al. Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta-analysis. Arthritis Care Res (Hoboken) 2020;72:838-49.
    1. Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703-8.

MeSH terms

LinkOut - more resources